<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Teva</title>
	<atom:link href="http://www.tapanray.in/tag/teva/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>The Game is Changing: Ensure Better Treatment Outcomes: Leverage Technology</title>
		<link>http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology</link>
		<comments>http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/#comments</comments>
		<pubDate>Mon, 03 Jun 2019 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[augmentation]]></category>
		<category><![CDATA[basic]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[Digihaler]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[medication]]></category>
		<category><![CDATA[non-drug]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[ProAir]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[replacement]]></category>
		<category><![CDATA[reSet]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[types]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9570</guid>
		<description><![CDATA[Today, several pharma players, mostly ‘encouraged’ by many non-pharma tech companies, are trying to gain, at least, a toehold in the digital health care space. It is visible even within the generic drug industry. Such initiatives, as they gain a &#8230; <a href="http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-game-is-changing-ensure-better-treatment-outcomes-leverage-technology/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is The Core Purpose of Pharma Business Much Beyond Profit Making?</title>
		<link>http://www.tapanray.in/is-the-core-purpose-of-pharma-business-much-beyond-profit-making/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-core-purpose-of-pharma-business-much-beyond-profit-making</link>
		<comments>http://www.tapanray.in/is-the-core-purpose-of-pharma-business-much-beyond-profit-making/#comments</comments>
		<pubDate>Mon, 10 Nov 2014 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[antibiotics]]></category>
		<category><![CDATA[Banks]]></category>
		<category><![CDATA[BBC]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Carmakers]]></category>
		<category><![CDATA[Chan]]></category>
		<category><![CDATA[Director]]></category>
		<category><![CDATA[Ebola]]></category>
		<category><![CDATA[expenditure. India]]></category>
		<category><![CDATA[general]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[Margaret]]></category>
		<category><![CDATA[margins]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Oil&gas]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[pupose]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[West]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6164</guid>
		<description><![CDATA[Dr. Margaret Chan, the Director General of the World Health Organization (WHO), at a briefing to discuss the Ebola outbreak in West Africa at the UN Foundation in Washington on September 3, 2014 said: “Big Pharma&#8217;s greed for profits, not &#8230; <a href="http://www.tapanray.in/is-the-core-purpose-of-pharma-business-much-beyond-profit-making/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-core-purpose-of-pharma-business-much-beyond-profit-making/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Kickbacks And Bribes Oil Every Part of India’s Healthcare Machinery” &#8211; A National Shame?</title>
		<link>http://www.tapanray.in/kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame</link>
		<comments>http://www.tapanray.in/kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame/#comments</comments>
		<pubDate>Mon, 07 Jul 2014 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[Avastin]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Berger]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[bribes]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[David]]></category>
		<category><![CDATA[Desai]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[gift]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[Johnson]]></category>
		<category><![CDATA[Ketan]]></category>
		<category><![CDATA[kickbacks]]></category>
		<category><![CDATA[Lucentis]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[means]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[MRs]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Nundy]]></category>
		<category><![CDATA[Parilamentary]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Samiran]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[Trade]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5584</guid>
		<description><![CDATA[“Corruption ruins the doctor-patient relationship in India” - highlights an article published in the well-reputed British Medical Journal (BMJ) on 08 May 2014. The author David Berger wrote, “Kickbacks and bribes oil every part of the country’s healthcare machinery and &#8230; <a href="http://www.tapanray.in/kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/kickbacks-and-bribes-oil-every-part-of-indias-healthcare-machinery-a-national-shame/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Big Pharma Receives Another Body Blow: Would Indian Slumber End Now?</title>
		<link>http://www.tapanray.in/big-pharma-receives-another-body-blow-would-indian-slumber-end-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-receives-another-body-blow-would-indian-slumber-end-now</link>
		<comments>http://www.tapanray.in/big-pharma-receives-another-body-blow-would-indian-slumber-end-now/#comments</comments>
		<pubDate>Mon, 19 May 2014 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[B]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[blow]]></category>
		<category><![CDATA[body]]></category>
		<category><![CDATA[bribery]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hepatitis]]></category>
		<category><![CDATA[Heptodin]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[Mark]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[receives]]></category>
		<category><![CDATA[Reily]]></category>
		<category><![CDATA[rip-off]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[slumber]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[Wake-up]]></category>
		<category><![CDATA[Xinhua]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5407</guid>
		<description><![CDATA[On May 13, 2014, The New York Times reported, while major pharmaceutical companies have been facing increased scrutiny of their marketing practices from governments around the world, last Wednesday the Chinese authorities sent a strong warning to the pharmaceutical industry &#8230; <a href="http://www.tapanray.in/big-pharma-receives-another-body-blow-would-indian-slumber-end-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-receives-another-body-blow-would-indian-slumber-end-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Credibility Erosion of Pharma Accelerating?</title>
		<link>http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-credibility-erosion-of-pharma-accelerating</link>
		<comments>http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/#comments</comments>
		<pubDate>Mon, 10 Mar 2014 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accelerating]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[credibility]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[erosion]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[USV]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5060</guid>
		<description><![CDATA[‘Big Pharma’ now seems to be desperately trying to gain the long lost high moral ground by pushing  hard its gigantic image makeover juggernaut, maintaining a strong pitch on the relevance of stringent Intellectual Property Rights (IPR) in the lives &#8230; <a href="http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-credibility-erosion-of-pharma-accelerating/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Threats to Indian Generics: Failing in US Inspections is Just Half The Story</title>
		<link>http://www.tapanray.in/threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story</link>
		<comments>http://www.tapanray.in/threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story/#comments</comments>
		<pubDate>Wed, 26 Feb 2014 09:44:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[Cleveland]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[commissioner]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[failing]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[half]]></category>
		<category><![CDATA[Hamburg]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[inspection]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[Margaret]]></category>
		<category><![CDATA[Ohio]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[story]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[Toansa]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Wellbutrin XL]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5027</guid>
		<description><![CDATA[At a recent event of the American Enterprise Institute, Dr. Harry Lever, a senior cardiologist at the Cleveland Clinic in Ohio, reportedly expressed his concern based on his personal experience regarding inconsistent quality among Indian generics. As a result, he requires switching patients &#8230; <a href="http://www.tapanray.in/threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/threats-to-indian-generics-failing-in-us-inspections-is-just-half-the-story/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>In the Wonderland of Pharma Generics: Some Steps In, Some Steps Over the Line</title>
		<link>http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line</link>
		<comments>http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/#comments</comments>
		<pubDate>Mon, 10 Jun 2013 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[allegations]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[blockbusters]]></category>
		<category><![CDATA[blocking]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Daiichi]]></category>
		<category><![CDATA[disparaging]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[entering]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[Holland]]></category>
		<category><![CDATA[Impax]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[NUT]]></category>
		<category><![CDATA[Opana]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[OxyContin]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[Purdue]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sankyo]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[TevaSante]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[ZydusCadila]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2234</guid>
		<description><![CDATA[To scale-up access to healthcare, especially for the marginalized population of any country, greater access to affordable generic drugs will always remain fundamental, besides improving healthcare infrastructure and its delivery mechanism. Thus, there should be a robust mechanism across the &#8230; <a href="http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-the-wonderland-of-pharma-generics-some-steps-in-some-steps-over-the-line/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>More Glivec Like Deals in China and Mounting Global Challenges: Innovators poised Joining Biosimilar Bandwagon</title>
		<link>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon</link>
		<comments>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/#comments</comments>
		<pubDate>Mon, 15 Apr 2013 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[12years]]></category>
		<category><![CDATA[AbVie]]></category>
		<category><![CDATA[advantage]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[bandwagon]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Genentech]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Hospira]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[joining]]></category>
		<category><![CDATA[LG]]></category>
		<category><![CDATA[low]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Remicade]]></category>
		<category><![CDATA[Rituxan]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2164</guid>
		<description><![CDATA[Pressure from the emerging markets on pricing of patented products is mounting fast. This time the country involved is China. Recently, the Health Minister of China who stepped down last month after a seven-year stint in the top health job &#8230; <a href="http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
